Context Therapeutics (CNTX)
Develops CD3-directed bispecific antibodies for solid tumors.
Something off on this page? Send us feedback.
Builds a portfolio of CD3-directed T-cell-engaging bispecific antibodies for solid tumors. Its programs include CTIM-76, CT-95, and CT-202; progress depends on clinical development, regulatory execution, and further capital.
Develops T-cell-engaging bispecific antibodies for solid tumors. Its pipeline includes CTIM-76, which targets CLDN6 and CD3, CT-95, which targets MSLN and CD3, and CT-202, which targets Nectin-4 and CD3. CT-95 was acquired, while CT-202 is subject to an exclusive worldwide license from BioAtla. The company is headquartered in Philadelphia and operates as a clinical-stage oncology developer.
CTIM-76 entered Phase 1 after Context discontinued its ONA-XR oral hormone-therapy program and redirected resources. The programs are designed around CD3-directed T-cell engagement; progress depends on clinical development, regulatory execution, and enough capital to support program spending.
Company facts
Target rangeAs of Sep 2, 2026
Latest analyst notes
No analyst notes in the last 24 months.
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $43.0M · Total debt $245.0K · Total assets $46.1M · Shareholders' equity $38.2M
- Revenue
- $0
- Operating income
- −$15.0M
- Net income
- −$14.6M
No dividends on record.
| Institutions61 holders · as of Mar 31, 2026 | 80.73% | 74.18M shares | |
| Insiders3 holders · as of Jun 10, 2025 | 1.23% | 1.13M shares | |
| Otherremainder | 18.04% | 16.57M shares |
91.88M company shares as of Sep 3, 2026 · institutions as of Mar 31, 2026 · holders as of their latest filing
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Evidence |
|---|---|---|---|
Bioimpact Capital LLCInstitution | 11.62% | 10.68M | 13Fas of Mar 31, 2026 |
Deep Track Capital, LPInstitution | 8.08% | 7.42M | 13Fas of Mar 31, 2026 |
Nextech Invest, Ltd.Institution | 8.08% | 7.42M | 13Fas of Mar 31, 2026 |
Soleus Capital Management, L.P.Institution | 7.58% | 6.96M | 13Fas of Mar 31, 2026 |
Soleus Capital Master Fund, L.P.Institution | 7.58% | 6.96M | 13Gfiled May 8, 2026 ↗ |
| See all 25 → | |||
13F — a manager's quarterly holdings · 13D/13G — an ownership statement filed at 5% or more
Insider tradesForm 4
No open-market trades in the last 12 months.
- Xencor
Direct clinical peer in CLDN6-targeted CD3 T-cell engagement
- BeOne Medicines (ADR)
Direct clinical peer in CLDN6×CD3 bispecific antibodies
- Pfizer
Commercial Nectin-4 ADC franchise in urothelial cancer
- Corbus Pharmaceuticals
Clinical Nectin-4 ADC program in head and neck and cervical cancers
ComparePre-market
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Context Therapeutics | $0.3517 | −4.01% | $33.3M | — | — | — | — |
| Xencor | $26.51 | −1.45% | $1.99B | — | — | 19.0 | +17.5% |
| BeOne Medicines (ADR) | $361.00 | −0.21% | $38.66B | 5.0 | 46.1 | 6.7 | +29.6% |
| Pfizer | $28.99 | −0.14% | $165.40B | 38.3 | 10.4 | 2.6 | +2.6% |
| Corbus Pharmaceuticals | $11.46 | +1.60% | $212.7M | — | — | — | — |
| Median | 21.7 | 28.2 | 6.7 | +17.5% |